PROVIDERS /// ONCOLOGY
Creating more options for your patients
Our collection of offerings uncover unique insights that empower you to customize treatment for individual patients, throughout their cancer journey.
CONTACT us
A comprehensive solution for all of your precision oncology needs
A comprehensive solution for all of your precision oncology needs
-
GENOMIC PROFILING
We deliver a comprehensive view of your patients through our tissue and liquid DNA profiling, somatic and germline testing, tumor-normal matched profiling and RNA sequencing.
-
AI-DRIVEN ALGORITHMS
We leverage our growing database to create specialized algorithms like Homologous Recombination Deficiency (HRD), Tumor Origin (TO), and DPYD, with more algorithms in development.
-
CLINICAL TRIAL MATCHING
We bring just-in-time clinical trial options to patients based on clinical and molecular data, for enrollment at your institution, through our TIME Trial Program—in days instead of months.
-
DIGITAL PATHOLOGY & AI
We are developing AI capabilities to help pathologists find actionable markers in specimens to identify potential patients for clinical trials or precision therapeutics.
-
FINANCIAL ASSISTANCE
We are committed to making our tests accessible for those in financial need. Most applicants who qualify pay no more than $100.
-
TEMPUS ONE
We bring our proprietary AI-enabled service platform to you in real-time, through our novel technology and online capabilities.
-
TEMPUS+
We provide select participating institutions with access to technical support, customized to meet the unique needs and goals of your cancer center.
-
EMR INTEGRATION
We offer easy access to current treatment options and relevant insights through our integration and connectivity capabilities.
Streamlining your workflow
One order. One platform. One financial assistance program.
Browse our FAQs-
4K+
oncologists rely on Tempus as their precision medicine partner
-
12K+
patients identified for potential enrollment into clinical trials
-
5M+
de-identified research records
-
20+
operational countries across Europe, Middle East, Asia, Central, and South America
-
UPCOMING WEBINAR:
Operational Metrics for the ELAINE II Study Combining a Traditional Approach With A Just-in-Time Model
This study demonstrates the success that Tempus’ TIME Trial Program had with Sermonix’s Elaine II trial for patients with ESR1-mutant, estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer.
Read more -
UPCOMING WEBINAR:
Use Of Clinical RNA-Sequencing In the Detection of Actionable Fusions Compared To DNA-Sequencing Alone
RNA-based, whole-exome sequencing provides a complementary method for fusion detection, and may improve the identification of actionable variants.
Read more -
UPCOMING WEBINAR:
Dual Tissue and Plasma Testing Improves Detection of Actionable Variants in Patients With Solid Cancers
Dual tissue and ctDNA testing, “dual testing”, improved identification of actionable variants compared with either modality alone.
Read more -
UPCOMING WEBINAR:
Nature Biotechnology Study Reveals that Tempus’ xT Platform Increases Cancer Patients’ Personalized Therapeutic Opportunities
Extensive molecular profiling combined with clinical data identifies targeted therapies and clinical trials for a large proportion of cancer patients, and paired tumor/normal plus transcriptome sequencing outperforms tumor-only DNA panel testing.
Read more -
UPCOMING WEBINAR:
Validation of a Liquid Biopsy Assay with Molecular and Clinical Profiling of Circulating Tumor DNA
Actionable variants would have been missed if only solid tumor or liquid biopsy tests were performed. Thus, we believe that liquid biopsies provide value to patients when used in combination with standard tissue genotyping.
Read more -
UPCOMING WEBINAR:
Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines
This study found that Tumor-normal (T/N) matched next-generation sequencing (NGS) has multiple advantages including enhanced variant classification and incidental germline variant discovery that may be missed with a guidelines-based approach.
Read more
Featured News and Events
view all news-
UPCOMING WEBINAR:
Tempus announces research collaboration with Intermountain Healthcare
The partnership will provide increased accessibility to Tempus’ multimodal datasets to further enhance Intermountain’s research program.
Read more -
UPCOMING WEBINAR:
Tempus provides access to Lilly Lung Cancer NGS Program for eligible mNSCLC patients
The Lilly Lung Cancer NGS Testing Program provides access to solid tumor and liquid biopsy comprehensive genomic sequencing at no cost for eligible mNSCLC patients.
Read more -
UPCOMING WEBINAR:
Tempus announces multi-year agreement with the VA NPOP
Tempus and the U.S. Department of Veterans Affairs (VA) National Precision Oncology Program (NPOP) will expand access to genomic testing and deliver personalized medicine for veterans with cancer.
Read more -
UPCOMING WEBINAR:
Eric Lefkofsky joins the Washington Post’s “Chasing Cancer” series
Tempus founder and CEO Eric Lefkofsky discusses the state of precision medicine with reporter Yasmeen Abutaleb.
Read more -
UPCOMING WEBINAR:
Tempus introduces the DPYD predictive diagnostic test to its growing collection of algorithms
The newest Tempus algorithmic predictive test assesses for relevant mutations in the DPYD gene and helps physicians better identify patients at potential risk for toxicity to certain chemotherapies.
Read more -
UPCOMING WEBINAR:
Tempus and Cedars-Sinai collaborate on a new precision medicine initiative
As part of the collaboration, Cedars-Sinai is leveraging Tempus’ genomic sequencing tests and data structuring capabilities for a variety of clinical and research efforts.
Read more
Validations and Resources
view all resources-
UPCOMING WEBINAR:
Tempus xT Validation
Our Tempus xT assay is designed to detect actionable oncologic targets by sequencing tumor samples with matched normal saliva or blood samples, when available.
Read more -
UPCOMING WEBINAR:
Tempus xF Validation
Our non-invasive Tempus xF liquid biopsy assay detects cell-free DNA (cfDNA) in blood specimens of advanced solid tumor patients.
Read more -
UPCOMING WEBINAR:
Standard Requisition Form
We offer an easy ordering process which allows you to order any of somatic and germline panels along with our add-on tests like HRD, TO and DPYD.
View here
-
Flora
“Having Tempus in my fight for cancer… it’s incredible.”
-
Bobbie
“I already know–thanks to [Tempus] testing–my first, second, and third lines of defense.”
-
Defne
“Without Tempus I couldn’t have reached any solution. It’s a new hope in life, for cancer.”
Partnering with Tempus is investing in the future
Every new test and data point strengthens our algorithms, predictions, and recommendations to improve treatment options for future patients.